Capricorn Fund Managers Ltd Invests $543,000 in Pfizer Inc. (NYSE:PFE)

Capricorn Fund Managers Ltd bought a new stake in shares of Pfizer Inc. (NYSE:PFEGet Rating) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund bought 9,189 shares of the biopharmaceutical company’s stock, valued at approximately $543,000.

Several other institutional investors also recently added to or reduced their stakes in the stock. Capital World Investors lifted its position in shares of Pfizer by 0.5% during the 3rd quarter. Capital World Investors now owns 241,360,858 shares of the biopharmaceutical company’s stock valued at $10,381,066,000 after acquiring an additional 1,171,443 shares during the period. Geode Capital Management LLC lifted its position in shares of Pfizer by 1.5% during the 4th quarter. Geode Capital Management LLC now owns 101,065,073 shares of the biopharmaceutical company’s stock valued at $5,952,333,000 after acquiring an additional 1,471,980 shares during the period. Morgan Stanley lifted its position in shares of Pfizer by 3.4% during the 2nd quarter. Morgan Stanley now owns 47,894,080 shares of the biopharmaceutical company’s stock valued at $1,875,532,000 after acquiring an additional 1,582,052 shares during the period. Franklin Resources Inc. lifted its position in shares of Pfizer by 28.8% during the 3rd quarter. Franklin Resources Inc. now owns 45,980,291 shares of the biopharmaceutical company’s stock valued at $1,977,614,000 after acquiring an additional 10,270,562 shares during the period. Finally, UBS Asset Management Americas Inc. raised its holdings in Pfizer by 2.0% during the third quarter. UBS Asset Management Americas Inc. now owns 23,728,801 shares of the biopharmaceutical company’s stock worth $1,020,576,000 after buying an additional 457,513 shares during the last quarter. Institutional investors own 66.50% of the company’s stock.

In other news, EVP William R. Carapezzi, Jr. sold 32,908 shares of the stock in a transaction dated Thursday, May 12th. The shares were sold at an average price of $50.00, for a total value of $1,645,400.00. Following the sale, the executive vice president now directly owns 38,146 shares of the company’s stock, valued at $1,907,300. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, SVP Jennifer B. Damico sold 4,000 shares of the stock in a transaction dated Monday, May 16th. The stock was sold at an average price of $50.50, for a total transaction of $202,000.00. Following the completion of the sale, the senior vice president now directly owns 15,064 shares in the company, valued at $760,732. The disclosure for this sale can be found here. 0.05% of the stock is owned by corporate insiders.

Several research firms have weighed in on PFE. Zacks Investment Research downgraded shares of Pfizer from a “buy” rating to a “hold” rating and set a $52.00 price objective on the stock. in a report on Tuesday, February 15th. JPMorgan Chase & Co. set a $57.00 price objective on shares of Pfizer in a report on Tuesday, May 3rd. The Goldman Sachs Group set a $51.00 price objective on shares of Pfizer in a report on Wednesday. Barclays set a $52.00 price objective on shares of Pfizer in a report on Tuesday, May 17th. Finally, Morgan Stanley assumed coverage on shares of Pfizer in a research note on Wednesday, April 6th. They issued an “equal weight” rating and a $55.00 target price for the company. Eleven research analysts have rated the stock with a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus price target of $57.00.

PFE traded up $0.30 during trading on Wednesday, hitting $53.71. 23,404,559 shares of the company traded hands, compared to its average volume of 30,863,920. The firm has a market cap of $301.36 billion, a P/E ratio of 12.32, a price-to-earnings-growth ratio of 0.61 and a beta of 0.76. The stock’s fifty day moving average is $51.44 and its 200 day moving average is $52.26. The company has a quick ratio of 1.13, a current ratio of 1.39 and a debt-to-equity ratio of 0.43. Pfizer Inc. has a one year low of $38.47 and a one year high of $61.71.

Pfizer (NYSE:PFEGet Rating) last released its quarterly earnings data on Tuesday, May 3rd. The biopharmaceutical company reported $1.62 EPS for the quarter, missing the consensus estimate of $1.66 by ($0.04). The business had revenue of $25.66 billion for the quarter, compared to analysts’ expectations of $24.73 billion. Pfizer had a net margin of 26.97% and a return on equity of 38.29%. Pfizer’s revenue for the quarter was up 76.8% compared to the same quarter last year. During the same period last year, the company earned $0.93 earnings per share. On average, equities research analysts forecast that Pfizer Inc. will post 6.63 EPS for the current fiscal year.

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, June 10th. Shareholders of record on Friday, May 13th will be issued a dividend of $0.40 per share. This represents a $1.60 annualized dividend and a yield of 2.98%. The ex-dividend date is Thursday, May 12th. Pfizer’s dividend payout ratio (DPR) is presently 36.70%.

About Pfizer (Get Rating)

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands.

Further Reading

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.